CuraGen Corporation

Quick facts

Phase 2 pipeline

• CG53135-05, velafermin · Wound healing
  Velafermin is a recombinant human fibroblast growth factor 2 (FGF-2) that stimulates angiogenesis and wound healing.

Phase 1 pipeline

• CR011-vcMMAE

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• CuraGen Corporation portfolio CI brief
• CuraGen Corporation pipeline updates RSS

Related

• Sector hub: All tracked pharma companies